No profile data available.
Axsome Therapeutics, Inc. (AXSM) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 1,346 full-time employees.
It reported revenue of $638.50 million for fiscal year 2025, up 65.5% from fiscal year 2024, and net income of -$183.17 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $218.38 million, up 45.5% from a year before. United States was its largest region in fiscal year 2025, with 98% of revenue. Its market capitalization was $8.82 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Axsome Therapeutics reported $638.50 million in revenue for fiscal year 2025, up 65.5% from $385.69 million in fiscal year 2024. In Q2 2026 revenue was $218.38 million.
United States: 98% of revenue by region in fiscal year 2025, followed by Outside of The United States (2%).
$8.82 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Biogen Inc. (BIIB), Neurocrine Biosciences, Inc. (NBIX), Jazz Pharmaceuticals plc (JAZZ), Praxis Precision Medicines, Inc. (PRAX).